Low Dose Aspirin And Age-related Macular Degeneration: Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,043,189.00
Summary
Age-related macular degeneration (AMD) is a major cause of visual impairment in advanced countries, responsible for nearly half of all legal blindness in Australia. Due to increased life expectancy, the number of people with this progressive late onset disease will double by 2025. Aspirin could prevent or delay the onset of AMD in older persons but its bleeding risk also needs to be considered. This project will determine whether treatment with low dose aspirin reduces incidence or progression o ....Age-related macular degeneration (AMD) is a major cause of visual impairment in advanced countries, responsible for nearly half of all legal blindness in Australia. Due to increased life expectancy, the number of people with this progressive late onset disease will double by 2025. Aspirin could prevent or delay the onset of AMD in older persons but its bleeding risk also needs to be considered. This project will determine whether treatment with low dose aspirin reduces incidence or progression of AMD.Read moreRead less
A Fibroin-based Prosthetic Bruch's Membrane For The Treatment Of Age-related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$538,080.00
Summary
Our aim is to develop a new therapy for the treatment of patients with age-related macular degeneration (AMD), a leading cause of blindness in our ageing population. The novelty of our therapy resides in using a protein derived from silk fibers (fibroin), to rebuild a healthy barrier between the outermost layer of the retina and adjacent blood vessels. We expect that the findings from this study will eventually lead to better outcomes for patients with AMD.
The vision we rely on every day to read and recognise faces depends upon the health of the central portion of our retina, the macula. Age-related Macular Degeneration (AMD) is the leading cause of blindness in Australia and the western world. Researchers at the Australian National University are collaborating to bring a new test for AMD severity to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them manage treatment.
Novel Functional Testing For Early Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$447,578.00
Summary
About 7.5% of Australians have diabetes and 62% of them will have signs of damage to their eyes within 6 years of diagnosis. Diabetes is 2 to 3 times more common amongst Aboriginal Australians. A group of researchers at the Australian National University are collaborating to bring a new test for the severity of diabetic eye disease to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them recognize sight-threatening damage and to assist in t ....About 7.5% of Australians have diabetes and 62% of them will have signs of damage to their eyes within 6 years of diagnosis. Diabetes is 2 to 3 times more common amongst Aboriginal Australians. A group of researchers at the Australian National University are collaborating to bring a new test for the severity of diabetic eye disease to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them recognize sight-threatening damage and to assist in treatment.Read moreRead less
Axon Degeneration And Axon Protection In CNS Disease And Injury
Funder
National Health and Medical Research Council
Funding Amount
$389,120.00
Summary
One of the major reasons for the clinical symptoms of neurological diseases such as Alzheimer’s disease and Motor Neuron Disease is the loss of connections between the nerve cells. Nerve cells are connected by specialized processes called axons. In disease these processes can breakdown. This project specifically looks at how axons break down in disease and tests therapeutic strategies to protect them.